2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Lung Neoplasms
1
Interventions
Specimen Handling
280
Magnetic Resonance Spectroscopy
233
pembrolizumab
220
Carboplatin
180
Cisplatin
146
Biopsy
146
Cyclophosphamide
138
Paclitaxel
128
Nivolumab
118
Bevacizumab
106
Gemcitabine
105
Radiotherapy
90
Dexamethasone
83
Pemetrexed
79
fludarabine
74
Docetaxel
74
atezolizumab
73
Fluorouracil
73
Doxorubicin
73
Radiation
72
Leucovorin
68
Rituximab
66
Oxaliplatin
64
venetoclax
60
Prednisone
60
durvalumab
58
Cetuximab
56
Vincristine
55
Etoposide
54
Lenalidomide
53
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adjuvants, Pharmaceutic
×
30 days
×
Clear all
NCT06788912
2026-06-01
MK-3475-01E
Merck Sharp & Dohme LLC
Phase 2
Recruiting
60 enrolled